Rainbow BioSciences LLC, a biotech subsidiary of Rainbow Coral Corp., today announced the newly formed collaboration of its latest acquisition target, Amarantus Biosciences Inc. (OTCPK:AMBS), with Brewer Sports International (NYSE:BSI). The partnership was established to increase awareness of new medical therapies being developed to treat traumatic brain injuries (NYSE:TBI) as a result of football and other contact sports.
The newly formed Coalition for Concussion Treatment is complementary to Amarantus' strategy of developing diagnostic and treatment options for TBI. Part of the coalition's mission is to educate parents, players, fans, and the sports community on the potential that new advances in developing new treatments can offer for acute symptoms, as well as the potential they carry for reducing the long-term effects of these injuries on the brain.
To increase awareness of these developments and products on a larger scale, the coalition is using social media and has created a viral campaign through Twitter and other digital and social media outlets.
The coalition recently achieved what it calls a "critical milestone" with its Twitter account announcing that 100 people have signed a petition endorsing the movement and seeking to disseminate critical information about promising new therapies that BSI plans to identify and raise awareness for in upcoming months.
Rainbow BioSciences said spreading the word of new advancements in treatments for traumatic brain injury is vital because it allows the broader community to support drug developers' efforts.
Rainbow BioSciences and Amarantus signed a letter of intent earlier this week.
For more information visit rainbowbiosciences.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net